Sarah Yuan

Rackspace MailGun Mimecast Amazon AWS reCAPTCHA Apache Mobile Friendly Google Tag Manager Google AdSense Remote AI

cell therapy biotech immunology autoimmune rheumatology biotechnology: biological products (no diagnostic substances) health care biotechnology research autoimmune diseases cd19-car t therapy b cell ablation caba-201 carta clinical trials reset immune system potentially curative treatments long-term immunosuppression neurology sle systemic lupus erythematosus myositis systemic sclerosis myasthenia gravis pemphigus vulgaris 4-1bb co-stimulatory domain investigational therapy phase 1/2 trials clinical efficacy safety profile biotechnology targeted therapy patient-centric approach chimeric antigen receptor t cells immunotherapy pa biomarker caba platform cell manufacturing deep durable responses fda fast track designation high unmet need patient enrollment immunosuppressants cytokine release syndrome icans clinical development program cd19 positive b cells durable remission autoimmune disorders patient-centered innovations transformative therapies clinical network collaborative research global expansion regulatory compliance clinical-stage engineered t cell therapies car t cell technology lupus carta strategy caart strategy innovative therapies fda alignment disease-specific campaigns manufacturing partnerships gene editing community engagement transformative cellular therapies durable responses dermatology precision medicine chronic management unmet medical needs strategic partnerships research & development philadelphia biotech community health wellness & fitness hospital & health care